No abstract available.
Vaccines*

Vaccines

No abstract available.
Vaccines*

28 lots of HB vaccine, produced from 1997 to 1999, have been tested for sterility, safety, potency and pyrogenicity. All of the 28 lots meet the WHO's requirements for human plasma-derived hepatitis B vaccine
Hepatitis B Vaccines ; Vaccines

Standard lyophylized rabid vaccine produced from CVS strain of Biopharma-Indonesia has met the criterion in terms of sterility, safety, efficacy (14.24 IU/ml), thermo-stability 37oC/month (5.4 IU/ml) and residual humidity (3.34%). Immune responsivity of the standard sample vaccine was determined by neutralizing method reaching 1/5 = 3.8 IU/ml; 1/25 = 1.7 IU/ml and 1/125 = 0.7 IU/ml
Rabies Vaccines ; Vaccines ; immunization

A purified rabie vaccine was prepared from mouse brain of CVS/P II from the Institute Bipharma-Indonesia. After refrigerating centrifuged, the vaccine was more pure and more efficacy. The sterility, innocuity and potency were perfect
Rabies Vaccines ; Vaccines ; immunization

The pilot study was performed on the first 5 lots of the Japanese encephalitis vaccine produced by Beijing-1 strain: JB011203, JB021203, JB030104, JB040204 and JB050304 to evaluate their safety and potency. The quality control consists of abnormal toxicity, specific safety, pyrogen, sterility and potency test. All of 5 lots were passed the minimum requirements of biological products of Japan. The mice and guinea pigs were healthy, body weigh increased. Non of bacteria and fungi grown in both medium Thioglycholate and Soybeancasein. The pyrogen test on rabbits was passed in 5/5 lots. Summed temperature response of 3 rabbits per lot were 0°C-0.3°C (WHO requirement ≤1.4°C). Potency test was evaluated by PRNT compared with reference EJP034A of BIKEN. After the second immunization the neutralizing antibody response > reference from 0.04 to 0.2 log. 5/5 lots were passed the safety and potency test and met the minimum requirement of biological products of WHO.
Japanese Encephalitis Vaccines ; Vaccines

Objectives: The World Health Organization recently revised their recommendations and considered healthy children and adolescents as low priority group for COVID-19 vaccine. This review comprehensively assessed existing clinical evidence on COVID-19 vaccine in 12-17 years old. Methods: Included in this review were any type of study that investigated the efficacy, immunogenicity, safety, and effectiveness of COVID-19 vaccine on protection against SARS-COV-2 infection in 12-17 years old. Various electronic databases were searched up to March 15, 2023. Studies were screened, data extracted, risk of bias appraised, and certainty of evidence was judged using GRADE. Review Manager 5.4 was used to estimate pooled effects. Difference between the two groups was described as mean difference for continuous variables and as relative risk or odds ratio for categorical variables. Results: There were six randomized controlled trials and 16 effectiveness studies (8 cohorts and 8 case control). Low certainty evidence showed that BNT162b2 (Pfizer) was effective, immunogenic, and safe in healthy adolescents. There were 15 effectiveness studies on BNT162b2 (Pfizer) in healthy adolescent and one on immunocompromised patients. It was protective against infection with any of the variants, with higher protection against Delta than Omicron. BNT162b2 is protective against hospitalization and emergency and urgent care (high certainty); and critical care and MIS-C (low). Very low certainty evidence noted that BNT 162b2 was also immunogenic in 12-21 years old with rheumatic diseases while on immunomodulatory treatment but with possible increased exacerbation of illness. Low certainty evidence demonstrated that mRNA-1273 (Moderna) was effective, immunogenic, and safe. Low to very low certainty evidence were noted on the safety and immunogenicity of two vector base vaccines (ChAdOx1-19 and Ad5 vector COVID vaccine) and two inactivated vaccines (CoronaVac and BBIBP CorV). Conclusion There is presently low certainty evidence on the use of RNA vaccines in 12-17 years old. The recommendation on its use is weak. There is presently insufficient evidence for the use of inactivated and vector-based COVID-19 vaccines. Different countries should consider whether to vaccinate healthy adolescent without comprising the other recommended immunization and health priorities that are crucial for this age group. Other factors including cost-effectiveness of vaccination and disease burden should be accounted.
mRNA Vaccines ; Vaccines, Inactivated

No Abstract available.
Vaccines, Combined*

No abstract available.
Vaccines, Combined*